Clinical Trial Update: A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection [Phase 2]

View source ↗

Summary

This is a Phase 2 trial update of a danoprevir boosted with low-dose ritonavir regimen, in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Danoprevir (danoprevir)
• Pegasys (pegylated interferon alfa-2a)
• Ritonavir (Ritonavir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED